A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder

Journal of Clinical Psychiatry

Volumn 65, Issue 1, 2004, Pages 37-43

  Denys, Damiaan ^a,b   Van Megen, Harold J G M ^a   Van Der Wee, Nic ^a   Westenberg, Herman G M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; PAROXETINE; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG RESISTANCE; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; OBSESSIVE COMPULSIVE DISORDER; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CROSS-OVER STUDIES; CYCLOHEXANOLS; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PAROXETINE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 1442284533     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0106     Document Type: Article

References (20)

1. Goodman WK, McDougle CJ, Barr LC, et al. Biological approaches to treatment-resistant obsessive compulsive disorder. J Clin Psychiatry 1993;54(suppl 6):16-26 (Pubitemid 23213609)
2. The Expert Consensus Panel for Obsessive-Compulsive Disorder. Treatment of Obsessive-Compulsive Disorder. J Clin Psychiatry 1997;58(suppl 4):2-72
3. Denys D, van der Wee N, van Megen HJ, et al. Double blind comparison of paroxetine and venlafaxine in obsessive-compulsive disorder. Int J Neuropsychopharmacol 2002;5:131-132
4. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33 (Pubitemid 29001829)
5. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
6. Arntz A, van Beijsterveldt B, Hoekstra R, et al. The interrater reliability of a Dutch version of the Structured Clinical Interview for DSM-III-R Personality Disorders. Acta Psychiatr Scand 1992;85:394-400
7. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 1: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011
8. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
10. Tournel G, Houdret N, Hedouin V, et al. High-performance liquid chromatographic method to screen and quantitate seven selective serotonin reuptake inhibitors in human serum. J Chromatogr B Biomed Sci Appl 2001;761:147-158 (Pubitemid 32817104)
11. Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002;5:181-191 (Pubitemid 34669829)
12. Koran LM, Saxena S. Issues and strategies in treating refractory obsessive-compulsive disorder. CNS Spectr 2000;5:24-31 (Pubitemid 30437255)
13. Hollander E, Bienstock CA, Koran LM, et al. Refractory obsessive-compulsive disorder: state-of-the-art treatment. J Clin Psychiatry 2002;63(suppl 6):20-29 (Pubitemid 34438946)
14. Piggott T. Pharmacotherapy of obsessive-compulsive disorder. Int Rev Psychiatry 1997;9:133-156
15. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404 (Pubitemid 34499333)
16. Roseboom PH, Kalin NH. Neuropharmacology of venlafaxine. Depress Anxiety 2000;12(suppl 1):20-29 (Pubitemid 30823408)
17. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001;179:15-22 (Pubitemid 32613392)
18. Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine [see comments]. Arch Gen Psychiatry 1990;47:577-585 (Pubitemid 20189970)
19. Barr LC, Goodman WK, Anand A, et al. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry 1997;154:1293-1295 (Pubitemid 27369184)
20. Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289-295